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Heparin-induced Thrombocytopenia Type II after Free 
Flap Operation
Jiwoong Baek, Jung Hyun Park, In-Ho Cha, Hyung Jun Kim
Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry
Abstract 
After radical excision of a tumor in the maxillofacial area, functional and esthetic reconstruction is needed, including flap 
surgery. Among the many etiologies of flap failure, venous thrombosis is one of the most frequent. Heparin is used routinely 
in the effort to avoid development of venous thrombosis. In rare cases, heparin-induced thrombocytopenia (HIT) type II 
occurs due to exposure to heparin. Heparin attached to platelet factor 4 forms a PF4/heparin-immunoglobulin G immune 
complex on platelet surfaces. This complex activates platelets, which leads to multiple coagulation in venous and arterial 
blood. We report here on a rare occurrence of HIT type II following fibula free flap surgery.
Key words: HIT type II, Heparin-induced thrombocytopenia, Free tissue flaps, Heparin
Introduction
Heparin-induced thrombocytopenia (HIT) type II is de-
fined as the formation of systemic thrombus accompanied 
by a more than 50% reduction of platelet count, with no 
other explanation than exposure to heparin[1].
HIT is important in reconstruction due to the inevitable 
use of heparin in free flap surgery[2]. Thrombocytopenia 
due to HIT type II influences flap survival. Even small 
amounts of heparin, such as from irrigation or a catheter 
coating, can trigger HIT[3]. During a low-platelet period, 
vascular conditions can give rise to a thrombus, which 
can cause organ failure and finally death[4].
There are two types of HIT. Type I HIT is momentary, 
occurring approximately four days after exposure to 
heparin. Minor thrombocytopenia springs up and is not 
associated with immunoglobulins. Type II HIT is mediated 
by immunoglobulin G (IgG) and manifests as a critical 
diminution in platelet count 4 to 14 days after exposure 
to heparin. Potentially fatal complications require immediate 
intervention[5]. However, this is unusual and rarely occurs.
Case Report
A 47-year-old man came to Department of Oral and 
Maxillofacial Surgery, Yonsei University College of Dentistry 
for evaluation and treatment of squamous cell carcinoma 
in the right mandibular retromolar area. The patient had 
no specific medical history, and baseline international nor-
malized ratio (INR) blood test was 1.06, and activated partial 
thromboplastin time (aPTT) was 29.6. Platelet count was 
242,000, and glutamic oxaloacetic transaminase (GOT)/ 
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Fig. 1. Preoperative magnetic resonance imaging (T2) view. Right
mandibular lesion extends to the masseter, medial pterygoid, and
mouth floor.
Fig. 2. Preoperative computed tomography lower extremity 
angiography. Both hyperplastic posterior tibial arteries were seen,
and no other remarkable lesion was observed.
Fig. 3. Evaluation of postoperative platelet count (19 days). On 
postoperative day 11, platelet count fell to 26,000/μL.
glutamic pyruvic transaminase (GPT) was 16/11, both within 
normal range. He had received treatment in a local clinic 
with repetitive curettage on the right third molar. Finally, 
the dentist performed a biopsy, from which squamous cell 
carcinoma was determined.
Following clinical evaluation, computed tomography 
(CT), magnetic resonance imaging (MRI) (Fig. 1), and posi-
tron emission tomography-CT (PET-CT), CT lower ex-
tremity angio (Fig. 2) examinations were performed. The 
center of the lesion was located in the right mandibular 
body, involving the right masseter and medial and lateral 
pterygoid muscles. The lesion extended to the right man-
dibular trigone and mandibular cortex, medullary portion. 
The right neck showed reactive lymph nodes at levels I 
and II. An operation was planned, and wide excision of 
the lesion, modified radical neck dissection on the right 
neck, supraomohyoid neck dissection on the left neck, 
and reconstruction of soft and hard tissue defect with a 
fibula free flap was performed. After the operation, the 
patient went into the intensive care unit (ICU). 
Subcutaneous injection of 5,000 units of un-fractioned hep-
arin was administered as an anti-thrombotic and com-
pression stockings were used on both legs. Daily routine 
lab tests were performed, including platelet count. Two 
days after the operation, the patient was moved from the 
ICU to the general ward. Seven days after the operation, 
the patient showed sudden hypooxygenation and dyspnea, 
and thus returned to the ICU.
Eight days after the operation, congestion was seen on 
the skin portion of the free flap area. A Doppler test was 
performed immediately and blood flow through vessels was 
maintained. Daily lab tests showed a slight reduction of 
the platelet count. Eleven days after the operation, the plate-
let count fell to 26,000/μL (Fig. 3). For evaluation of sys-
temic thrombosis, an ultrasonography test was performed 
on the legs and arms, and a chest CT was taken, which 
showed pulmonary thromboembolism and partial pulmo-
nary infarction. The 4 T’s test indicated a more than 50% 
reduction in platelet count within 5 to 10 days after the 
operation and thrombus formation with no other remark-
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able reason. Evaluation of the 4 T’s test was performed, 
yielding a score of 8 points, the highest score. HIT type 
II was strongly suspected. 
A hematologist was consulted immediately. Clinically, 
HIT type II was diagnosed. Heparin in any amount what-
soever was discontinued. Because the patient had no spe-
cific renal insufficiency, and thromboses were found, we 
could select argatroban or lepirudin or danapariod based 
on American College of Chest Physicians Evidence-Based 
Clinical Practice Guidelines (currently, 2012 American 
CHEST physicians’ guidelines are the newest[6]).
Intravenous argatroban (Novastan; Mitsubishi Tanabe 
Pharma Korea, Seoul, Korea) 10 mg with infusion of 100 
mL normal saline was started, and dose was regulated to 
target INR=2.5 and aPTT=50 to 55 seconds using an in-
fusion pump, which was approximately two times the pa-
tient’s baseline. Monitoring of aPTT was performed at 
2-hours intervals. 
Fourteen days after the operation, the platelet count began 
to increase. Argatroban was maintained for 25 days, followed 
by coumadization. On discharge, the patient's platelet count 
was 366,000/μL, and INR was 2.58. The skin portion of 
the flap was partially dead and was therefore removed. The 
muscular and bone portion of the flap finally survived.
Discussion
There are many causes of flap failure, including thrombosis. 
Jeon et al.[7] reported a free flap survival rate of 98.8% 
among 164 cases. Total failure occurred in two cases, other 
complications included partial flap necrosis, delayed heal-
ing of donor site, infection, and fistula formation. 
Heparin is used routinely for maintenance of blood flow 
and prevention of thrombosis. Its most common complica-
tion is bleeding. HIT type II is a rare disease compared 
to other complications, exposure of heparin constituting 
its predisposing factor. Although there is no bleeding ten-
dency in HIT type 2, there is usually systemic coagulation.
Smythe et al.[8] reported that the incidence of HIT type 
II is 0.2%. Warkentin et al.[9] reported that the incidence 
may increase to 1% in the context of major surgery. After 
the operation, damaged endothelial cells cause platelets 
and platelet factor 4 (PF4) to become more active, increas-
ing the likelihood of HIT. Use of low molecular weight 
heparin (LMWH) decreases the incidence of HIT. 
HIT type II is associated with an immune reaction related 
to IgG, which binds to heparin and forms negatively charg-
ed antibodies against PF4. The antibodies bind with neg-
atively charged PF4, forming a complex involved in platelet 
activation, coagulation, and endothelial activity. Platelet 
factor is accelerated by cross-linking of heparin-IgG/PF4 
complex, which can lead to strong coagulation. Reduction 
of platelet count occurs 4 to 14 days after exposure to 
heparin, but can occur within as little as 24 hours[10].
HIT type II may cause three critical complications: pul-
monary embolism, adrenal failure, and acute anaphylactoid 
reaction. Venous thrombosis occurs in 25% to 75% of HIT 
type II patients, and approximately one fourth of them 
have arterial thrombosis (4:1 venous to arterial ratio). 
Approximately 25% of HIT type II patients experience adre-
nal failure and adrenal vein thrombosis may develop into 
adrenal hemorrhagic necrosis. Development of acute renal 
crisis can occur when adrenal glands are bilaterally dead.
Manifestations of anaphylactoid reaction include acute 
hypertension, dyspnea, fever, chills, chest pain, and tachy-
cardia, with severe cases resulting in respiratory or cardio-
genic arrest. In our case, the patient showed dyspnea seven 
days after the operation and re-entered the ICU.
Because of these risk factors, Warkentin[10] recom-
mended that HIT type II patients should receive care in 
the ICU. Based on reported cases, approximately 4% to 
5% of HIT type II patients are at risk of death[4].
For prevention of HIT, unfractioned heparin (UFH) can 
be replaced by LMWH, which generally shows lower in-
cidence of HIT than UFH. However, the risk of HIT remains 
with LMWH, which is more costly. 
Although HIT is clearly dangerous, there is no viable 
replacement for heparin, drugs such as direct thrombin 
inhibitor (DTI) notwithstanding. Heparin, the most val-
uable anti-thrombotic drug, has the advantages of not going 
over liver and kidney and its anti-thrombotic effect can 
be easily reversed by protamine. In addition, DTI agents 
such as argatroban and lepirudin should be regulated using 
bleeding markers such as partial thromboplastin time value, 
complicated and laborious work, which can easily fail. 
Most patients who receive heparin therapy are free of HIT.
For evaluation of flap survival, the clinician must perform 
an inspection for several signs. Detection of congestion 
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and swelling, which is sometimes fatal to flap survival, 
is dependent on repeated color inspection, pressure test 
for perfusion, and ultrasonic Doppler test. If thrombosis 
accompanied by an abrupt decrease in platelet count is 
observed, the clinician should consider the possibility of 
HIT type II, whose conclusive diagnosis requires recovery 
of platelet count after discontinuing heparin. Other diag-
nostic methods for HIT type II are platelet serotonin-release 
assay, heparin induced platelet activation test, IgG-specific 
PF4-dependent enzyme immunoassays, and polyspecific 
enzyme immunoassays[11]. As these lab tests take consid-
erable time, the clinician often reaches a diagnosis based 
on the clinical situation. In this case, these lab tests were 
not performed due to lack of assay facilities.
It is important that clinicians understand the following: 
when thrombosis is found, its cause must be determined. 
Virchow’s triad is useful in this respect. Virchow proposed 
that three elements can lead to development of thrombosis: 
stasis, changes in the vessel wall, and changes in the blood. 
If there are no other reasons for thrombosis and platelet count 
starts to decrease, the 4 T’s scoring system can be utilized[12]. 
Elements include 1) platelet fall, 2) timing of platelet fall, 
3) thrombosis or other clinical sequelae, and 4) other causes 
of thrombocytopenia not evident. Each element counts for 
0, 1, or 2 points. The sum of the points indicates the risk 
value for HIT, with low risk being 0 to 3 points, intermediate 
risk 4 to 5 points, and high risk 6 to 8 points.
If HIT type II is presumed, immediate consultation to 
a hematologist is necessary. Prognosis of HIT type II is 
dependent on early detection and early treatment. Five 
steps recommended for handling a diagnosis of HIT type 
II include stopping all heparin medication, consultation 
to a hematologist, use of another antithrombotic agent, 
imaging study for thrombosis, and study of antibodies[12].
We used argatroban instead of heparin. After discontinu-
ing heparin, the platelet count starts to increase. In treat-
ment of HIT, additional heparin injection is not allowed, 
as this can cause massive coagulation followed by systemic 
thrombosis.
DeBois et al.[13] recommended at least two platelet 
counts per week when using heparin. American CHEST 
physicians’ guidelines[6] recommend one platelet count per 
two days. As the operation can increase the incidence of 
HIT type II, we propose a daily platelet count check two 
weeks post-operatively. HIT type II usually starts 4 to 14 
days after the operation. 
HIT type II is a rare disease related to heparin exposure, 
which leads to coagulation disorder. Local or systemic co-
agulation may cause flap failure and other fatal 
complications. When flap congestion accompanied by an 
abrupt decrease in platelet count occurs for no particular 
reason, the clinician should consider HIT type II. Early 
diagnosis and treatment is essential.
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